-+ 0.00%
-+ 0.00%
-+ 0.00%
Cadre Holdings (CDRE) Earnings Strength Raises The Question Of Whether Shares Still Look Cheap
Share
Listen to the news

Cadre Holdings (CDRE) is drawing investor attention after reporting strong annual revenue growth and higher operating profits, tied to improved efficiency and better use of fixed costs within its safety equipment business.

See our latest analysis for Cadre Holdings.

Cadre Holdings’ share price has fallen 29.33% year to date to US$29.06, with a 4.75% decline over the past 90 days, even though the 3 year total shareholder return is 31.38%. This suggests longer term holders have still seen gains.

If this kind of mixed momentum has you comparing ideas, it could be a good time to widen your search and check out the 18 top founder-led companies

Given Cadre Holdings’ share price pullback alongside growth in revenue and operating profits, the key tension now is simple: is most of the gains already behind the stock, or is there still meaningful upside ahead as valuation comes into focus?

Most Popular Narrative: 37.9% Undervalued

The most followed narrative on Cadre Holdings pegs fair value at $46.80 versus the last close of $29.06. This frames the recent pullback as a valuation gap that hinges on future execution and cash flow delivery.

The company's robust pipeline of high-margin M&A targets, paired with disciplined capital allocation, is expected to drive scale, operational leverage, and long-term adjusted EBITDA growth, with free cash flow generation supporting both organic growth and shareholder returns.

Read the complete narrative.

Want to see what sits behind that confidence in Cadre Holdings? The narrative leans heavily on rising margins, faster earnings growth, and a premium future earnings multiple that needs careful scrutiny.

Result: Fair Value of $46.80 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Cadre Holdings story could look very different if large contract awards are delayed again or if recent acquisitions fail to deliver expected cost benefits.

Find out about the key risks to this Cadre Holdings narrative.

Next Steps

With sentiment around Cadre Holdings split between concern and optimism, use the latest data, including its 2 key rewards and 3 important warning signs, to form your own view quickly by checking the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Cadre Holdings?

If Cadre Holdings has your attention, do not stop there. Use the Simply Wall St screener to keep building a watchlist that truly fits your goals.

  • Target resilient cash generators by reviewing the 47 high quality undervalued stocks that combine quality fundamentals with prices some investors may be overlooking.
  • Zero in on reliable income prospects by scanning the 8 dividend fortresses that focus on higher yields supported by underlying business strength.
  • Prioritize capital protection by checking the 82 resilient stocks with low risk scores that aim to limit downside while still offering meaningful equity exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending